FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pJIA), a rare form of juvenile arthritis

Basel, 15 May 2018 FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pJIA), a rare form of juvenile arthritis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active... Read more

Elsevier Teams up With PerkinElmer to Enable Faster, More Intuitive Chemistry Research

First phase of a long-term collaboration set to improve the research experience by integrating flagship solutions ChemDraw and Reaxys New York, May 8, 2018 Elsevier, the information analytics business specializing in science and health, has today announced a strategic collaboration with PerkinElmer. The first phase of this collaboration will see the integration of Elsevier’s flagship chemistry... Read more

FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

Basel, 07 May 2018 FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority... Read more

FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

Basel, 07 May 2018 FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority... Read more

TAN/TBN titration in petrochemical samples – walk away automation for up to 112 samples

5/1/2018 Metrohm is pleased to present a fully automated solution for the determination of Total Acid Number (TAN) and Total Base Number (TBN) in up to 112 samples. This solution is based on the OMNIS Sample Robot and addresses the needs of QC laboratories in the petrochemical industry as well as contract laboratories looking for... Read more

Californians remain concerned about future droughts; Support recycled water as a long-term solution for water security

SACRAMENTO, Calif.–(BUSINESS WIRE)–Apr. 30, 2018– Although 2017 brought significant rainfall to a dry state, Californians remain very concerned about future droughts, and the vast majority support using advanced technologies to generate new water supplies when needed. A statewide survey conducted in late 2017 found that an overwhelming majority of California residents believe another drought is... Read more

QIAGEN announces FDA approval of PartoSure

Germantown, Maryland, and Hilden, Germany, April 20, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of PartoSure®, which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The pre-market approval of PartoSure by the U.S. Food and... Read more

New Online Sulfur Analyzer Enables Real-Time Data Analysis in the Oil and Gas Industry

New Online Sulfur Analyzer Enables Real-Time Data Analysis in the Oil and Gas Industry The next-generation Thermo Scientific SOLA iQ total sulfur analyzer is designed for process optimization and offers improved ease-of-use and connectivity over existing analyzers FRANKLIN, Mass., April 18, 2018 /PRNewswire/ — The new Thermo Scientific SOLA iQ online sulfur analyzer helps technicians, engineers... Read more

FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors

Basel, 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison Roche (SIX: RO, ROG;... Read more

FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors

Basel, 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison Roche (SIX: RO, ROG;... Read more